Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC S versus COREG CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC S versus COREG CR.
BETOPTIC S vs COREG CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist. In ophthalmic use, it reduces intraocular pressure by decreasing the production of aqueous humor, likely through blockade of beta-2 receptors in the ciliary epithelium.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Instill 1 drop in the affected eye(s) twice daily.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours in adults; prolonged in renal impairment and in elderly patients due to decreased clearance.
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Renal: 0.3% unchanged; extensive hepatic metabolism to inactive metabolites; biliary/fecal elimination of metabolites accounts for the majority of excretion; total renal elimination of drug and metabolites is approximately 80%, with the remainder via feces.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Category C
Category C
Beta-Blocker
Beta-Blocker